Skip to content

SmartGlass-Guided ERCP with Cannulation of Native Papilla 1.0

Remote Assistance Via Smart Glasses Compared to In-person Assistance for Cannulation of the Native Papilla During Endoscopic Retrograde Cholangiopancreatography

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06683716
Acronym
EmeRald
Enrollment
170
Registered
2024-11-12
Start date
2025-01-02
Completion date
2026-12-31
Last updated
2024-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Tract Diseases, Pancreatic Diseases

Keywords

Telemedicine, Training Technique, Cholangiopancreatography, Endoscopic Retrograde

Brief summary

The aim of this prospective randomized study is to evaluate whether telemedical assistance via SmartGlasses is equivalent to physical presence in teaching Endoscopic Retrograde Cholangiopancreaticography (ERCP) in terms of examination success and safety. Endoscopic papilla cannulation is a key skill for successful ERCP and therefore a measurable primary endpoint of the study. This can be measured as the time (in seconds/minutes) between stable visualization of the papilla and successful endoscopic cannulation of the target structure (bile duct or pancreatic duct).

Detailed description

In sparsely populated regions of a country and where there is a lack of experienced specialists, it may not always be possible to have an experienced ERCP examiner present during an examination. Therefore, telemedical examination assistance via a connection to data glasses worn by the examiner is a possible option to replace the physical presence of an instructor or experienced ERCP examiner. The aim of this prospective randomized study is to evaluate whether telemedical assistance via smart glasses is equivalent to physical presence in terms of examination success and safety. Endoscopic papilla cannulation is a key skill for successful ERCP and therefore a measurable primary endpoint of the study. This can be measured as the time (in seconds/minutes) between stable visualization of the papilla and successful endoscopic cannulation of the target structure (bile duct or pancreatic duct). In addition to other efficacy endpoints, adverse events, which are expected to be rare, will be documented at 48-hour intervals and calculated as a rate. Telemedical 'live' support of an ERCP via data glasses has not yet been demonstrated or tested in a trial. To ensure the safety of the examination under these circumstances, the training examiner is present in the neighbouring room and can physically assist or take over the examination at any time if necessary.

Interventions

OTHERTraining in presence of the instructor

The instructor gives the trainee instructions for the examination while he/she is present in the examination room.

OTHERTelemedically training by an instructor

The trainer gives instructions to the trainee through a telemedical connection to the examiner using SmartGlasses

Sponsors

Helios Kliniken Schwerin
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

Prospective randomised non-inferiority trial comparing two training conditions in gastrointestinal endoscopy (ERCP)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients aged ≥ 18 years without previous papillotomy

Exclusion criteria

* Cannulation of the minor papilla necessary * Significant comorbidity * Haemodynamic instability * Pregnant women * Refusal or inability to give written informed consent for the study * Instructor had to perform the examination himself/herself

Design outcomes

Primary

MeasureTime frameDescription
Papilla cannulation timeDuring the intervention: from the stable visualisation of the papilla until the successful cannulation of the papilla, assessed up to 60 minutesTime to cannulate the native papilla during ERCP

Secondary

MeasureTime frameDescription
Adverse events during and after ERCPTime interval between insertion of the endoscope through the mouth up to 48 hours after ERCPAll adverse events that occur during ERCP and after ERCP: number (n)

Countries

Germany

Contacts

Primary ContactDaniel Schmitz, Dr. med.
daniel.schmitz@helios-gesundheit.de+49-385-520-2601
Backup ContactMartin Kliment, Dr.med.
Martin.Kliment@helios-gesundheit.de+49-385-520-2601

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026